The cloning of a family of genes that encode the melanocortin receptors
Mountjoy KG, Robbins LS, Mortrud MT, Cone RD
Science (1992)
The original cloning paper for the melanocortin receptor family — identification of the murine and human MSH receptor and the human ACTH receptor as G-protein-coupled receptors, deposited in GenBank as X65633, X65634, and X65635. The molecular foundation of every melanocortin-targeted peptide on this site.
This is the original molecular cloning paper for the melanocortin receptor family, published in Science in 1992 by Kathleen Mountjoy, Lawrence Robbins, Marilyn Mortrud, and Roger Cone at the Vollum Institute and Oregon Health Sciences University. The paper used a combination of Northern blotting, polymerase chain reaction with degenerate primers based on conserved G-protein-coupled receptor transmembrane domains, and sequence homology analysis in mouse and human tissues to identify the genes encoding the melanocyte-stimulating hormone (MSH) receptor and the adrenocorticotropic hormone (ACTH) receptor as members of a subfamily of G-protein-coupled receptors.
The paper deposits three GenBank sequences corresponding to the murine MSH receptor (X65633), the human MSH receptor (X65634), and the human ACTH receptor (X65635) — the molecules subsequently designated MC1R (melanocortin-1 receptor, the α-MSH receptor primarily expressed on melanocytes) and MC2R (melanocortin-2 receptor, the ACTH receptor on adrenal cortex). The receptors are characterized as Gs-coupled with cAMP / PKA downstream signaling and are placed in a structural subfamily related to (but distinct from) the cannabinoid receptor family. The functional characterization extends to receptor distribution: MC1R expression on melanocytes (consistent with α-MSH's pigmentation effects) and MC2R expression on adrenal cortex (consistent with ACTH's cortisol-stimulation effects).
The paper opens the molecular-pharmacology era of the melanocortin system. The three other receptor subtypes — MC3R, MC4R, and MC5R — were cloned subsequently by the Cone group and other laboratories over the following years, completing what is now characterized as the five-receptor melanocortin family. The MC4R cloning is the load-bearing identification for the modern obesity and feeding-circuit pharmacology, with the MC4R-null mouse obesity phenotype and the human MC4R loss-of-function obesity genetics anchoring the modern feeding-circuit framing. The MC4R subtype is also the receptor most directly relevant to the PT-141 / bremelanotide peptide FDA-approved for premenopausal acquired generalized hypoactive sexual desire disorder. The MC1R subtype is the receptor relevant to the KPV peptide (though notably the KPV anti-colitis mechanism was shown to be PepT1-mediated and MC1R-independent in Kannengiesser et al. 2008) and to the melanotan-II broad melanocortin agonist used in gray-market tanning markets. The melanocortin-receptor entry in the peptide receptor pharmacology atlas starts here.
The paper is the molecular-cloning entry point for the melanocortin family — the foundational identification rather than the comprehensive pharmacology characterization. The three other receptor subtypes (MC3R, MC4R, MC5R) and their distinct tissue-distribution and physiological-role profiles required subsequent papers by the Cone group and others over the following several years to characterize. The Gs-cAMP-PKA signaling architecture proposed in the paper is correct at the canonical level but has been refined extensively in the intervening decades — biased agonism at MC4R, β-arrestin recruitment patterns, allosteric modulation, and the agouti and AgRP endogenous-antagonist biology all add layers that the original cloning paper could not anticipate. The receptor subtype selectivity of the melanocortin peptide drug class (afamelanotide, melanotan-II, bremelanotide / PT-141, setmelanotide) is built on the cloning identifications from this paper plus the subsequent MC3R/MC4R/MC5R papers; the chronology matters because subtype-selectivity claims that pre-date a particular subtype's cloning rest on inference rather than direct receptor-binding characterization. The pharmacological landscape of the receptor family — particularly the contribution of MC3R to feeding biology, the role of MC5R in exocrine glands and immune cells, and the broader anti-inflammatory pharmacology of α-MSH and its tripeptide fragments characterized in Brzoska et al. 2008 — sits in the literature that built outward from this cloning paper and is the context the corpus-peptide pages assemble. The melanotan-II safety record (pigmented-lesion changes, atypical-mole development, case reports of melanoma in chronic high-dose users) is the principal modern caution for unsupervised broad melanocortin-agonist use; the cloning paper is the molecular foundation, not a safety document.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.